



**“No Sweat”
In Just Three Minutes**

May 15, 2019

84M
US adults
suffer
from
excessive
sweating

70%

Alter lifestyle to
cope with condition

47%

Choose
clothing to
hide sweat

35%

Avoid raising
arms



▷ Significant Quality of Life Impact

HYPERHIDROSIS

Bothersome sweating

Sweat causes social anxiety and embarrassment

Sweating disrupts normal daily activities

Sweat beyond physiological needs regardless of temperature

Sweat soaks through clothing or drips off hands

84 Million Adults Suffer from Excessive Sweating

Sources: Census Bureau: Population Division and Income, Poverty, and Health Insurance Coverage in the United States, 2017; International Hyperhidrosis Society – Harris Interactive Survey of 2,897 U.S. adults aged 18+, June 2008 and 2004

THE CANDESANT SOLUTION

Administered in
a physician's
office

Non-invasive,
topical
treatment


Applied to the
underarm

Stays on for
***less than 3
minutes***

Minimal
discomfort, no
downtime



▶ Targeted Energy to Reduce Sweat

INTERACTION BETWEEN ALKALI METALS & WATER



- Generates heat precisely at the site of the water (sweat)
- Heat is controlled by the amount of metal and sweat present

FLEXIBLE, THREE-LAYER PATCH



- 1 REDUCES SWEATING**
Generates enough heat to inactivate the sweat gland
- 2 INHIBITS BACTERIA**
Bacteria cause the odor associated with sweat

▶ The Candesant Procedure

- Axilla cleaned and dried
- Patch placed on the skin
- Subjects experience a feeling of warmth on skin surface
- Total device application time up to 3 minutes
- Patch removed, axilla cleansed

Initial Feasibility Study Sweat Reduction Sustained for 6+ Weeks

69% - average sweat reduction

All responders across 6 weeks of follow-up


Improvement 24 hours post treatment

Demonstrated quantitative reduction at week 1

Effect peaked and sustained at weeks 3 – 6

89% still responding at week 6

- Average response rate of 73%



▶ Favorable Safety Profile

- 3 treatment related adverse events in total
 - All were mild in severity
 - Treated with topical steroid or Neosporin; resolved without incident
- 2 non-treatment related events
 - Both were mild and resolved without further treatment

Efficacy Without Unpleasant Side Effects

	Efficacy	Durability (>6 Weeks)	No Capital Expense	Side Effects	Multifocal Application
Candesant Patch	✓	✓	✓	Mild Irritation	✓

		Efficacy	Durability (>6 Weeks)	No Capital Expense	Side Effects	Multifocal
INVASIVE	Botox Injections	✓	✓	✓	Painful Up to 50 injections	Limited
	Energy devices <i>Thermal destruction of sweat gland</i>	✓	✓	✗	Very painful Potential nerve damage	✗

NON- INVASIVE	OTC/Rx Antiperspirants	Minimal	✗	✓	Irritation Daily Use	Limited
	Medications	Mixed	✗	✓	Dry eye, dry mouth Daily use	✓
	Iontophoresis	Limited	✗	✓	Time consuming and inconvenient	Hands/feet only ✗

▷ Attractive to Physicians



LEVERAGES EXISTING PATIENTS

Large, existing patient base already getting other cosmetic procedures

Looking for the “next thing”

Incremental revenue to the practice



FITS WELL INTO OFFICE PORTFOLIO

No capital expense

Low risk to bring into the practice

Minimal training required



PROFITABLE PROCEDURE

Minimal incremental chair time

Extenders can perform the procedure

Attractive “entry level” price point

Source: Physician/KOL research, 2015, 2016

▶ Multiple Product Segment Opportunities



In-Office Procedure

- Non-invasive, can be done by a nurse or PA
- No capital outlay to the physician
- Incremental business to the practice



Home-Use Device

- Convenient, private application
- Extend results
- Sold as physician dispensed product – same customer as CDX-101



OTC Licensing Opportunity

- Technology can be incorporated into existing aluminum based products
- Allows existing OTC products to last longer (>48 hours)



Deeply Experienced Team



NIQUETTE HUNT – President and CEO

- 25+ years experience in general management and commercialization
- Raised over \$250MM in 2014 IPO and follow-on financing
- Launched 20+ products across multiple verticals in consumer medicine
- Increased sales, profits and/or market share on every business managed



JESSE ROSEN, VP PRODUCT DEVELOPMENT

- Over 20 years in design, development and manufacturing
- Experience building and managing teams at early-stage and large medical device companies
- Designed and launched flagship products for myoscience and Zeltiq



JACOB WAUGH, MD – Chief Scientific Officer

- Co-Founder, Revance Therapeutics
- Pioneered *in vivo* tissue engineering
- Developed first clinically proven macromolecule delivery system
- Prolific inventor – 400+ worldwide patents pending; 40+ issued



MARY BETH KREISSLER, CFO

- 20 years experience with pre-revenue and early commercialization stage companies in tech and life sciences
- Helped to launch and lead finance for SmartThings, WillowPump, Nuelle, Qatalyst Partners, and DOTS Devices



MICHAEL KANE, MD – Chief Medical Officer

- Prominent Plastic Surgeon – New York City
- Industry experience as an entrepreneur and consultant to Allergan, Galderma, and Merz
- Author of 100+ publications and books

▶ Highlights



>\$2 BILLION INITIAL MARKET OPPORTUNITY

More than 84 million people in the U.S. sweat too much
Limited treatment options



RECURRING SELF-PAY REVENUE STREAM

Lifelong condition, significant quality of life impact
Established distribution channel



CLINICAL EFFICACY

Achieved primary and secondary endpoints
6+ Weeks of “No Sweat”



LOW CAPITAL REQUIREMENTS TO MAJOR MILESTONES

Capital efficient execution
Prototype development complete



EXPERIENCED TEAM

Proven track record in developing and launching products
Deep industry experience